RxDoctor Payments Data

John Beary, MD

Rheumatology · Montgomery, OHNPI 1619901055

Payments from drug & device makers

$9,146in general payments, 2019–2025

Across 594 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Johnson & Johnson$1K
  • Lilly USA, LLC$770
  • Amgen$755
  • Novartis$573
  • UCB, Inc.$527
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$8,64495%
  • Education$5015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie274$3,587
Johnson & Johnson80$1,402
Lilly USA, LLC55$770
Amgen(2 entities)45$755
Novartis30$573
UCB, Inc.27$527
AstraZeneca17$321
Pfizer18$301
E.r. Squibb & Sons, L.L.C.14$249
GSK9$148
Organon7$135
Sandoz4$71
Sobi, Inc3$62
Mallinckrodt Hospital Products Inc.1$60
Aurinia Pharma U.S., Inc.3$55
Scilex Pharmaceuticals Inc.2$42
Mylan Institutional Inc.2$31
Genentech USA, Inc.1$22
Biocon Biologics Inc1$19
Boehringer Ingelheim1$17

How this compares

$9,146 in reported general payments places this provider in the 70th percentile of 255 rheumatology providers in Ohio.

See all rheumatology providers in Ohio

Medicare billing

Part B allowed, 2024
$54,022
Medicare patients
75
Services billed
1,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab49$328,544
Enbrel SureclickEtanercept11$76,831
MethotrexateMethotrexate Sodium131$2,340
Colchicine27$2,158
Prednisone146$1,259
Hydroxychloroquine Sulfate40$1,209
Allopurinol102$717
Meloxicam11$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Colchicine$42$2,15827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 255 rheumatology providers in Ohio.

Other rheumatology in Montgomery

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →